CLINICAL_TRIALS
trial_result
· 2014-10-06
Clinical Trial Update: Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD [Phase 3]
Summary
Phase 3 trial evaluating Bevasiranib plus Lucentis for wet age-related macular degeneration was terminated, with results posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: OPKO Health, Inc. | Conditions: Macular Degeneration | Phase 3 | Status: TERMINATED | Results posted: 2014-10-06